9/6/ % 25% 25% 25%

Size: px
Start display at page:

Download "9/6/2012 25% 25% 25% 25%"

Transcription

1 Objectives Risky (Factor) Business: Preoperative Evaluation for the Primary Care Physician David M Schneider, MD Faculty Physician, Santa Rosa Family Medicine Residency 9/6/12 By the end of this conference, attendees will be able to: 1. Identify minimum functional level for perioperative safety. 2. State which lab tests should be done preoperatively on a routine basis. 3. State at least one step in preop cardiac evaluation. 4. Identify at least 1 low risk surgery. 5. State which pts should definitely get preop β- blockers. 6. Remember at least 1 fact about the movie Risky Business. Case 1 You are called at 0200 by a surgeon to see a pt with abdominal pain. The surgeon tells you the pt is an 86 yo white male with CHF with RLQ abdominal pain, tenderness at McBurney s point, and a fever to CBC shows WBC of Case 1 - continued Surgeon: Please clear this pt for surgery. I think I should wait until the morning and have cardiology do an echo. What do you do? 33% 86 yo M w/h/o CHF & Appy sx/sx echo? 33% 1. Yes echo echo only 33% 2. Yes echo echo + Cardio eval 3. No Clearance for Surgery Does clear for surgery mean there are no risks? Your task is to find the risks. Risks vary based on many factors. Your other key tasks: Optimize medical condition of the surgical pt. Propose strategies to reduce risk & complications. 1

2 Clearance for Surgery 2 As a medical consultant, generally avoid the phrase clear for surgery. Cardiologists & surgeons felt it was important to clear pt for surgery, anesthesiologists did not. It is the anesthesiologist s duty to recommend type of anesthesia not yours. Anesthesiologists felt it was unimportant for consultant to recommend type of anesthesia, cardiologists & surgeons disagreed. What Should You Consider in Preop Evaluation? My approach = the 4 C s: Conditioning (general condition of pt) Cardiac Chest (lungs) Clots (VTE prophylaxis) AnesthAnalg 1998;87:830-6 What Should You Consider in Preop Evaluation? My approach = the 4 C s: Conditioning (general condition of pt) Cardiac Conditioning 1 MET = metabolic demand at rest. Increased perioperative risk in pts unable to perform at 4 METs. Walk up 2 flights of stairs. Run a short distance. Walk up a hill 1 2 blocks. Carry 2 bags of groceries up 1 flight of stairs. Walk 2 4 blocks (flat). Simple questions on history. AmJCardiol 1989;64:651-4; 4; Circulation 2009;120:e169-e276; e276; ArchIM 1999;159: ; 92; Chest 2001;120: Risky Business Trivia Bob Seger s 1 st Billboard- Charted Song 1. Old Time Rock & Roll 2. Ramblin Gamblin Man 3. Get Out of Denver 4. Katmandu 25% 25% 25% 25%

3 Does Age Matter? Maybe. Older studies found risk w/ age. Recent studies found mortality & pulmonary morbidity w/advancing age. Other studies have not found mortality. After adjusting for other morbidities, impact of age is relatively small. Avoid ageism: age alone is not a reason to withhold surgery. Speaking of General Condition What about labs? NEJM 1977;297:845-50; 50; AnnSurg 1982;195:90-6; EffClinPract 2001;4:172-7; 7; AnnIM 2006;144:581-95; JAMA 1989;261: ; 15; AnnIM 2001;134:637-43; 43; MedClinNorthAm 1993;77: Which Should Be Ordered as Routine Preop Lab? 1. CBC 2. Coag Studies 3. Basic Chem Panel 4. EKG 5. Other Routine Preop Testing BC Electrolytes, glc, Cr EKG XR PT/PTT Preop Testing vs None Ambulatory surgery pts: no difference in perioperative adverse events. ataract surgery: no difference. holecystectomy (teaching hospital): 2.1% of tests abnormal & potentially significant, 0.66% resulted in action, 0.16% benefitted from preop management changes. AnesthAnalg 2009;108:467-75; 75; Cochrane Database Syst Rev. 2012;3:CD007293; ArchIM 1987;147: Preop Testing vs None 2 Elective surgery: 60% of tests not needed; 0.22% w/abnormality possibly affecting periop management, none of these were acted on & no adverse consequences. Elective surgery, asymptomatic pts: 4.2% of tests abnormal (18.8% predictable by H&P), 29.4% of these (1.2% of all pts) prompted more eval 0.26% of all pts required treatment, no surgeries delayed, no association between lab abnormality and adverse outcome. JAMA 1985;253: ; 81; MayoClinProc 1991;66:

4 Preop Testing vs None 3 Review of studies of preop testing: Normal test does not reduce chance of postop complications for nearly all tests evaluated. Exceptions: + LR 3 4 (small increase in likelihood of disease if test is +) only for electrolytes, Hgb, renal function. Clinical evaluation predicts most abnormalities. Preop management changed by test result in only 0 3% of cases. MedClinNorthAm 2003;87:7-40; What About Coags? Unexpected & clinically significant bleeding disorders are unusual. Most bleeding disorders are evident on history. Most common reasons for PTT are mild factor XII deficiency & lupus anticoagulant neither is assoc d w/bleeding or postop complications. JAMA 1985;253: ; 81; BrJAnaesth 2011;106:1-3; ClinApplThrombHemost 2004;10: ; 204; ArchIM 1995;155: ; 15; JThrombHaemost 2006;4:766 73; 73; JAMA 1986;256:750-3; CanJAnaesth. 2006;53(6 Suppl):S12-20; 20; MedClinNorthAm 2003;87:7-40 What About Coags? 2 History or questionnaire is at least as accurate as lab tests to predict clinically significant bleeding. Routine Preop Testing Routine preoperative testing in asymptomatic patients is not indicated (even PT/PTT). Selective preop testing based on likelihood of underlying condition that might affect perioperative management. HOWEVER: know your local surgeons patterns and practices. You are not likely to change them, so make sure your pts get the care they need. Assessment of Cardiac Risk ardiovascular complications are the most common & serious perioperative complications. Pts > 40 yo (unselected): 1.4% periop MI. Pts w/some CV risk factors: 3.2% periop MI. Pts w/pad: RR 3.1 for all-cause mortality, 5.9 for CV mortality, 6.6 for death d/t CAD. 1/3 of periop deaths are due to cardiac causes. Chest 2006;130: ; 596; NEJM 2001;345: ; AnnIM 2011;154:523-8; Anesthesiology 1998; 88: ; 578; AmJSurg 1997;174:755-8; MedClinNorAm 2001;85: ; N EJM 1995;333:1750-6; ; N EJM 1992;326:381-6; 6; surgery?source=search_result&search=preop+eval&selectedtitle=1~150#h21 Assessment of Cardiac Risk 2 30 million surgeries/yr in US. >8 million w/cv risk factors or CAD. 50,000 periop MI s. Most (74%) occur within 48 hrs of surgery. Most pts (65%) did not have ischemic sx. Difficult to diagnose % mortality. Prevention is important. Chest 2006;130: ; 596; NEJM 2001;345: ; AnnIM 2011;154:523-8; Anesthesiology 1998; 88: ; 578; AmJSurg 1997;174:755-8; MedClinNorAm 2001;85: ; N EJM 1995;333:1750-6; ; N EJM 1992;326:381-6; 4

5 Revised Cardiac Risk Index (RCRI) 20 years after the original Goldman risk index, a simplified method for determining cardiac risk in noncardiac surgery. Derived & validated in original study (1999). Validated at another institution (2010). Limitations: Less accurate for vascular noncardiac surgery, esp AAA. Predicts cardiac, but not all-cause, mortality (it s a cardiac index duh!). RCRI 2 Easy to use. ACC/AHA finally incorporated RCRI into its algorithm for preop eval. Easy to remember. Circulation 1999;100:1043-9; 9; AnnIM 2010;152:26-35; ; CMAJ 2005;173: D R RCRI Mnemonic Which is NOT Part of the RCRI (DR C 4 )? 1. Diabetes 2. Dysrhythmia 3. CAD 4. Cerebrovascular Dz 25% 25% 25% 25% David M Schneider, MD D R RCRI Mnemonic David M Schneider, MD RCRI Mnemonic Diabetes requiring insulin Risky surgery (intrathoracic, vascular) (intrathoracic, intraperitoneal, AD (including + test, EKG, etc) HF erebrovascular dz hx r > 2.0 David M. Schneider, MD Circulation 1999;100:

6 RCRI Interpretation ount the risk factors to estimate cardiac mortality! 0 0.4% [<1%] 1 1.0% [1%] % [5%] 3 or more % [10%] Some later studies had higher death rates, but similar predictive value of increasing RCRI score. Circulation 1999;100: ; CMAJ 2005;173: RCRI Predicts CV Morbidity, Too VFib/Cardiac arrest omplete heart block MI Pulmonary edema Circulation 1999;100: Risky Business Trivia 2 Curtis Armstrong Played Joel s Friend Miles in Risky Business. His Next Role? 1. Goov (Clan of Cave Bear) 2. Herbert Quentin Burt Viola (Moonlighting) 3. Booger (Revenge of Nerds) 4. Ronnie (Coneheads) 25% 25% 25% 25% Steps to Eval of CV Risk in Surgical Pts ACC/AHA updated guideline, A bit cumbersome, but mostly manageable. E A R L I Mnemonic for Steps in ACC Algorithm (i.e., early eval for CV dz) David M Schneider, MD 6

7 Mnemonic for Steps in ACC Algorithm Emergency? Active cardiac conditions? Risk of surgical procedure Limitation (functional capacity) Index (RCRI) In Other Words 5 steps: 1. Is surgery an emergency? 2. Does pt have active cardiac conditions? 3. Is it a low risk surgery? 4. Does pt have good functional capacity? 5. What clinical or surgery-related related risk factors does pt have by the RCRI? David M Schneider, MD Step 1 Does the surgery need to be done emergently? Yes go to OR! Perioperative surveillance. Postop risk stratification & management. No go to step 2. 25% 25% Which Active Cardiac Condition is NOT a Contraindication to Surgery? 25% 1. Unstable angina 25% 2. Decompensated CHF 3. Symptomatic Aortic Stenosis 4. 2 AV Blk Type I (Wenkebach) Step 2 Are there active cardiac conditions? Acute/unstable coronary syndromes Blocks/arrhythmias CHF Severe stenoses Yes evaluate & treat per ACC guideline. No go to step 3. Active Cardiac Conditions Acute/unstable coronary syndromes Unstable or severe angina (NYHA/CCS III or IV). Acute or recent MI (within 30 days). May include stable angina in patients who are unusually sedentary. 7

8 Grading Angina Active Cardiac Conditions 2 anadian CV Society 1. Sx only w/strenuous activity 2. Sl limitation sx w/vigorous activity 3. Mod limitation sx w/everyday living activities 4. Severe limitation sx w/any activity rest NYHA 1. No limitation of activity no sx w/ ordinary activity 2. Sl limitation sx w/ordinary activity 3. Mod limitation sx w/less-than-ordinary activity 4. Severe limitation sx w/any activity rest Blocks/significant arrhythmias: High-grade grade AV block. Mobitz II AV block. Third-degree degree AV heart block. Symptomatic ventricular arrhythmias. Supraventricular arrhythmias (including atrial fib) w/uncontrolled ventricular rate (HR > rest). Newly recognized ventricular tachycardia. Symptomatic bradycardia. Active Cardiac Conditions 3 Decompensated Congestive heart failure NYHA class IV Worsening or new onset HF Severity of CHF NYHA Class I - symptoms of HF only at activity levels that would limit normal individuals. Class II - symptoms of HF with ordinary exertion. Class III - symptoms of HF with less than ordinary exertion. Class IV - symptoms of HF at rest. Same scale as NYHA angina grading (or CCS). Active Cardiac Conditions 4 Severe valvular disease Severe aortic stenosis Symptomatic mitral stenosis (progressive DOE, exertional presyncope, HF) Step 3 Risk of surgery Low risk surgery proceed to OR. Not low risk go to step 4. 8

9 Which is a Low Risk Surgery? Risks of Surgery 1. Mastectomy 2. Tonsillectomy 3. Total Knee Replacement 4. Appendectomy 25% 25% 25% 25% High risk (>5% CV events): Aortic and other major vascular surgery Peripheral vascular surgery Intermediate risk (1-5%): Intraperitoneal and intrathoracic surgery Carotid endarterectomy Head and neck surgery Orthopedic surgery Prostate surgery AmJMed 2005;118, ; 1141; Circulation 2009;120:e169-e276; e276; EurHeartJ 2009;30: Risks of Surgery 2 Low risk surgery (<1% CV events) generally no additional CV testing required: Ambulatory surgery Breast surgery Cataract surgery Derm/Superficial procedure Endoscopic procedures Step 4 Functional Limitation: Functional capacity 4 METs w/o sx go to OR. Functional capacity < 4 METs w/o sx go to step 5. Walk up 2 flights of stairs. Walk 2 4 blocks (flat). Step 5 Here is where the RCRI comes in. Score 0 go to OR. Score 1 2 either: Surgery w/possible β-blocker if it will change mgmt. Consider noninvasive testing. Score 3: Vascular surgery consider further testing (if it will change management) & β-blocker. Intermediate risk surgery surgery w/possible β- blocker OR consider noninvasive testing. RCRI Mnemonic Diabetes requiring insulin Risky surgery (intrathoracic, vascular) (intrathoracic, intraperitoneal, AD (including + test, EKG, etc) HF erebrovascular dz hx r > 2.0 David M. Schneider, MD Circulation 1999;100:

10 25% Who Should Get β-blocker? 25% yo F carotid endarterectomy 25% yo M colonoscopy yo F already on β-blocker 25% Mastectomy yo M liver transplant (no GIB) Surgery w/β-blocker vs More Testing Insufficient data. 1-2 risk factors: 2 studies in vasc surg pts showed no difference in outcomes. 3 risk factors: Degree of cardiac stress (change in HR, BP, vascular volume, pain, bleeding, clotting tendencies, oxygenation, neurohumoral activation, other) may help determine risk of periop cardiac events & need for testing. JCardiothoracVas Anesth 2003;17:694-8; JACC 2006;48:964-9 Perioperativeβ-Blockers onflicting early data: 1996: Periop atenolol mortality & CV complications for 2 yrs in pts w/cad or CAD risk. Above study of? validity small # s, risk factors & meds not identical. DECREASE, 1999: preop bisoprolol MI & CV events by 90%.? Validity small # s, unblinded, stopped early. β -blocker evidence considered unreliable. Perioperativeβ-Blockers : No benefit in DM pts. Periop β-blockers in-hosp mortality only in high risk pts. NEJM 1996;335: ; N EJM 1996;335:1761-3; 3; AmJMed 2005;118:1413; NEJM 1999;341: ; 94; EurHeartJ 2001;22:1353-8; JAMA 2005;294:2203-9; 9; BMJ 2005;331: BMJ 2006;332:1482; NEJM 2005;353: POISE Study Large RCT, 8351 pts w/atherosclerosis or risk. High dose metoprolol succinate vs placebo. Hold for HR < 50 or SBP < 100. Combined endpoint CV death, nonfatal MI, or nonfatal cardiac arrest. 16% in 1 endpoint, ARR = 1.1% NNT = 91. MI by 27%, ARR = 1.5% NNT = 67. Total mortality 33%, NNH = 125. CVA 117%, NNH = 200. Hypotension 55%, NNH = 19. Lancet 2008;371: More on β-blockers Only 2% in POISE had RCRI 3.?? benefit. Meta-analysis analysis 2008: No all-cause mortality, CV mortality, HF. 35% nonfatal MI (NNT=63). Doubling in nonfatal strokes (OR=2.01, NNH=293). Other risks: Periop bradycardia: NNH = 22. Periop hypotension: NNH = 17. No increased risk of bronchospasm. Lancet 2008;372:

11 ACC/AHA Recs on β-blockers lass I (benefit >> risk), intervention should be done: Continueβ-Blockers in pts already taking (LOE C = consensus opinion, limited studies). ACC/AHA Recs on β-blockers 2 lass IIa (benefit > risk, more studies needed, reasonable to do intervention), LOE B (limited info, 1 RCT or some unrandomized): Beta blockers titrated to HR & BP probably recommended for pts undergoing vascular surgery who are at high cardiac risk d/t CAD or cardiac ischemia on preoperative testing. Circulation 2009;120:e169-e276; e276; JAMA 2001;285: ; 1873; NEJM 1999;341: ; Ann Surg 2009;249:921 6 ACC/AHA Recs on β-blockers 3 lass IIa (benefit > risk, more studies needed, reasonable to do intervention), LOE B (limited info, 1 RCT or some unrandomized): Beta blockers titrated to HR & BP are reasonable for patients undergoing intermediate-risk risk surgery in whom preoperative assessment identifies CAD or RCRI > 1. ACC/AHA Recs on β-blockers 4 lass IIa (benefit > risk, more studies needed, reasonable to do intervention), LOE C (consensus opinion, limited studies): Beta blockers titrated to HR & BP are reasonable for pts in whom preoperative assessment for vascular surgery identifies high cardiac risk, as defined by RCRI > 1. Circulation 2009;120:e169-e276; e276; JAMA 2001;285: ; 1873; NEJM 1999;341: ; Ann Surg 2009;249:921 6 ACC/AHA Recs on β-blockers 4 lass IIb The usefulness of beta blockers is uncertain for pts who are undergoing either intermediate-risk risk procedures or vascular surgery in whom preoperative assessment identifies a single clinical risk factor in the absence of coronary artery disease. (LOE C) The usefulness of beta blockers is uncertain in patients undergoing vascular surgery with no clinical risk factors who are not currently taking beta blockers. (LOE B) Summary on β-blockers ontinue β-blockers in pts already taking them. Probably: Pts w/cad on preop testing (or known hx) undergoing vascular surgery. onsider: Pts w/known CAD or RCRI > 1 undergoing intermed risk surgery. RCRI >1 in undergoing vascular surgery. 11

12 How to Use β-blockers β-1 1 selective preferred. Atenolol may be superior to metoprolol. 1 study did not differentiate between metoprolol tartrate (regular) & succinate (sustained release). Other study included pts on both metoprolol forms. POISE used metoprolol succinate. Bisoprolol more selective, no comparative data. When to Give β-blockers Begin poβ-blockers at least 7 30 days before surgery, if possible, to enhance efficacy. IV β-blockers (atenolol > metoprolol) may be given shortly before surgery. BMJ 2005;331:932-8; Anesthesiology 2011;114:824-36; NEJM 1999;341: ; 94; JACC2010;56:1922-9; 9; Am HeartJ 2006;152:983-90; 90; Lancet 2008;371: Who Should Get Preop EKG? Who Should Get Preop EKG? 1. Nobody 2. Everybody yo M smoker + low risk surg 4. Known CAD + intermed risk surg 25% 25% 25% 25% lass I Recommended for pts RCRI 1 who are undergoing vascular surgical procedures LOE B). Recommended for pts w/known CHD, PAD, or cerebrovascular disease who are undergoing intermediate-riskrisk surgical procedures (LOE C). lass IIa Reasonable in persons with no clinical risk factors who are undergoing vascular surgical procedures. (LOE B). Maybe Preop EKG? lass IIb Preoperative resting 12-lead ECG may be reasonable in patients with RCRI 1 who are undergoing intermediate-riskrisk operative procedures (LOE B). lass III Preoperative and postoperative resting 12- lead ECGs are not indicated in asymptomatic persons undergoing low-risk surgical procedures (LOE B). Controversy: Another View 2009 retrospective study reviewed EKG s, 5 predictors of significantly abnormal EKG : Risk Factor Sensitivity 87.6%, specificity 59.5%. OR CHF Angina 7.49 MI 6.16 Severe valvular dz 4.80 Age > High cholesterol 2.26 Anesthesiology 2009;110:

13 What s Wrong With This Data? 1. It s Disease-Oriented Evidence 2. Retrospective Study 3. Not Pt-Oriented Evidence that Matters 4. Predict EKG findings, not pt outcomes 5. All the above Noninvasive Stress Testing lass I Pts w/active cardiac conditions in whom noncardiac surgery is planned eval eval & Tx per ACC/AHA guidelines (LOE B). lass IIa Pts w/3 or more clinical risk factors (RCRI) and poor functional capacity (less than 4 METs) who require vascular surgery reasonable if it will change management (LOE B). Noninvasive Stress Testing 2 lass IIb Noninvasive stress testing may be considered for patients with at least 1 to 2 clinical risk factors and poor functional capacity (less than 4 METs) who require intermediate risk or vascular surgery if it will change management. (Level of Evidence: B) Noninvasive Stress Testing 3 NOTE: stress testing has high NPV (90+%), low PPV (6 67%, 18% in one review). Useful in predicting low risk if neg. Not as useful identifying high risk if +. Circulation 2009;120:e169-e276; e276; NEJM 1995;333:1750-6; Circulation 2006;113: Echocardiography Reasonable (Class IIa, LOE C): Dyspnea of unknown etiology. Current or prior CHF w/worsening dyspnea or other change in clinical status if LV function has not been assessed within last 12 months. Summary Higher risk more preop testing and more treatment (β-blockers). Pt risk factors Risk of surgery Cards consult: Acute cardiac condition. High risk surg + intermed risk pt, or vice versa. If you are not sure or comfortable. 13

14 ACC says: Class I Perioperative Statins Continue statins in pts currently on statin and scheduled for noncardiac surgery (LOE B). Class IIa For pts undergoing vascular surgery with or without clinical risk factors, statin use is reasonable (LOE B). Class IIb For pts w/at least 1 clinical risk factor who are undergoing intermediate-risk risk procedures, statins may be considered (LOE C). Perioperative Statins Evidence says: Statins may prevent A Fib in pts undergoing cardiovascular & non-cardiac surgery. 40% reduction in A Fib, even in pts already on β-blockers. Statins reduce periop mortality, MI, ischemia. Some conflicting evidence. These are high risk pts consistent w/acc rec. Tune in again next time. NEJM 2009;361:980-9; JVascSurg 2004;39:967-75; 75; JAMA 2004;291:2092-9; 9; Circulation 2003;107: ; JACC 2005;45:336-42; 42; AmJCardiol 2007;100:316-20; 20; JThorCardiovasc Surg 2008;135: ; 411; AnnThorCardiovascSurg 2011;17:376-82; ArchSurg 2012;147: CV Risk Assessment: Not Quite Ready For Prime Time NSQIP (Nat l Surgical Qual Improvement Prog) Large retrospective study, internally validated. Type of surgery Dependent functional status Abnormal creatinine American Society of Anesthesiologists' class Age Performed better than RCRI. Online calculator: diacarrest Circulation.2011;124:381-7; CV Risk Assessment: Not Quite Ready For Prime Time 2 Erasmus index Same as RCRI, adds age Retrospective, not yet validated. Ankle-Brachial Index (ABI) High risk population (19% DM, 14% CAD). ABI performed similarly to RCRI. Abnormal ABI OR of for cardiac complication. AmJMed 2005;118: ; 1141; AnesthAnalg 2008;107: Case 1 You are called at 0200 by a surgeon to see a pt with abdominal pain. The surgeon tells you the pt is an 86 yo white male with CHF with RLQ abdominal pain, tenderness at McBurney s point, and a fever to CBC shows WBC of Surgeon: Please clear this pt for surgery. I think I should wait until the morning and have cardiology do an echo. 33% 86 yo M w/h/o CHF & Appy sx/sx echo? 33% 1. Yes echo echo only 33% 2. Yes echo echo + Cardio eval 3. No 14

15 Let s Make it Crystal Clear CT shows inflamed appendix In Other Words 5 steps: 1. Is surgery an emergency? 2. Does pt have active cardiac conditions? 3. Is it a low risk surgery? 4. Does pt have good functional capacity? 5. What clinical or surgery-related related risk factors does pt have by the RCRI? In Other Words 5 steps: 1. Is surgery an emergency? YES go to OR! What Have We Learned? 1. Functional limitations (4 METs) 2. Ageism 3. Preop labs 4. Preop CV risk assessment 1. RCRI 2. ACC guidelines ( EARLI ) 3. Active cardiac conditions 4. Risks of surgeries 5. Preop EKG s What Have We Learned? 2 5. Periop management 1. Β-blockers 2. Statins 3. Preop cardiac testing What Should You Sometimes Say, per Miles? 1. The question isn't "what are we going to do," the question is "what aren't we going to do? 2. College women can smell ignorance 3. Sometimes you gotta say, What 33% 33% 33%

Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing

Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis Michael A. Blazing Outline The coming crush A practical approach to clinical risk assessment Classic approach to

More information

Perioperative Cardiac Evaluation

Perioperative Cardiac Evaluation Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

How to Keep Your Surgeon Out of Trouble: Perioperative Medicine: Risk Stratification

How to Keep Your Surgeon Out of Trouble: Perioperative Medicine: Risk Stratification How to Keep Your Surgeon Out of Trouble: Perioperative Medicine: Risk Stratification Jalal K. Ghali, M.D., F.A.C.C. Professor of Medicine Associate Chair for Clinical Research Chief, Division of Cardiology

More information

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

ECG may be indicated for patients with cardiovascular risk factors

ECG may be indicated for patients with cardiovascular risk factors eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,

More information

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation. DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart

More information

PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care

PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care Ronald L Walsh, D.O., MACOI, FACC ACOI Clinical Challenges in Inpatient Care March

More information

Pre-Operative Cardiac Evaluation Kalpana Jain, MD

Pre-Operative Cardiac Evaluation Kalpana Jain, MD Pre-Operative Cardiac Evaluation Kalpana Jain, MD Cardiac evaluation is an integral part of pre-op evaluation. Perioperative cardiac events are common causes of mortality. Major cardiac complications associated

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

CARDIAC RISKS OF NON CARDIAC SURGERY

CARDIAC RISKS OF NON CARDIAC SURGERY CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management

More information

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular Mitral Regurgitation Anatomy Mechanisms of MR Presentation Evaluation Management Repair Replace Clip

More information

In patients undergoing noncardiac surgery, preoperative

In patients undergoing noncardiac surgery, preoperative LEE A. FLEISHER, MD Robert D. Dripps Professor and Chair, Department of Anesthesiology and Critical Care, and Professor of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA Cardiac

More information

Perioperative myocardial infarction. for Perioperative Cardiac Events. Paul Lee, M.D., M.P.H. Perioperative Cardiac Risk in Non-Cardiac Surgery

Perioperative myocardial infarction. for Perioperative Cardiac Events. Paul Lee, M.D., M.P.H. Perioperative Cardiac Risk in Non-Cardiac Surgery Perioperative Cardiac Risk in Non-Cardiac Surgery Perioperative Cardiac Risk in Non-Cardiac Surgery Paul Lee, M.D., M.P.H. Associate Clinical Professor of Medicine Medical Director, Section of Hospital

More information

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of

More information

Preoperative Laboratory and Diagnostic Studies

Preoperative Laboratory and Diagnostic Studies Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Perioperative management of the

Perioperative management of the Preoperative Cardiac Risk Assessment BERNARD M. KARNATH, M.D., University of Texas Medical Branch at Galveston, Galveston, Texas Heart disease is the leading cause of mortality in the United States. An

More information

Episode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier

Episode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier Episode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier Most common dysrhythmia seen in ED, and incidence increasing with ageing population Presentation Common presentations: younger patients often

More information

Inpatient Heart Failure Management: Risks & Benefits

Inpatient Heart Failure Management: Risks & Benefits Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical

More information

Atrial Fibrillation Management Across the Spectrum of Illness

Atrial Fibrillation Management Across the Spectrum of Illness Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,

More information

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications

More information

Atrial Fibrillation The Basics

Atrial Fibrillation The Basics Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology Chapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00-E89) The diabetes mellitus codes are combination codes

More information

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:

More information

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

More information

Anticoagulation For Atrial Fibrillation

Anticoagulation For Atrial Fibrillation Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator

More information

Efficient Evaluation of Chest Pain

Efficient Evaluation of Chest Pain Efficient Evaluation of Chest Pain Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL No Disclosures Outline Background Chest pain pathway Indications for stress test Stress test

More information

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is

More information

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary

More information

Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care

Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care Guideline on Perioperative Cardiovascular Evaluation Dr.Kevin Kannan, Dept. of Cardiology, OhioHealth Conflict of Interest No relevant

More information

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated

More information

INTRODUCTION TO EECP THERAPY

INTRODUCTION TO EECP THERAPY INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

Update in Perioperative Medicine 2016

Update in Perioperative Medicine 2016 Update in Perioperative Medicine 2016 Kurt Pfeifer, MD, FACP, FHM Professor of Medicine Medical College of Wisconsin No conflicts of interest to disclose Learning Objectives Utilize the ACC/AHA guidelines

More information

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,

More information

EVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL CENTER

EVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL CENTER American University of Armenia Center for Health Services Research and Development Nork Marash Medical Center EVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL

More information

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469)

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Provider Checklist-Outpatient Imaging Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Medical Review Note: Per InterQual, if any of the following are present,

More information

CARDIAC CARE. Giving you every advantage

CARDIAC CARE. Giving you every advantage CARDIAC CARE Giving you every advantage Getting to the heart of the matter The Cardiovascular Program at Northwest Hospital & Medical Center is dedicated to the management of cardiovascular disease. The

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

ACC/AHA Pocket Guidelines

ACC/AHA Pocket Guidelines ACC/AHA Pocket Guidelines Perioperative Cardiovascular Evaluation for Noncardiac Surgery A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines ACC/AHA

More information

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia

More information

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial Vascular Quality Initiative - Carotid Artery Stent Last Name First Name Middle Initial Date of Birth Medical Record Social Security General Information Patient Data Zip/Postal Code Gender Male Female Ethnicity

More information

Emergency Scenario. Chest Pain

Emergency Scenario. Chest Pain Emergency Scenario Chest Pain This emergency scenario reviews chest pain in a primary care patient, and is set up for roleplay and case review with your staff. 1) The person facilitating scenarios can

More information

New Anticoagulants and GI bleeding

New Anticoagulants and GI bleeding New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit

More information

ACUTE ATRIAL FIBRILLATION TREATMENT IN THE SURGICAL PATIENT

ACUTE ATRIAL FIBRILLATION TREATMENT IN THE SURGICAL PATIENT DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

Ischemic Heart Disease: Angina Pectoris

Ischemic Heart Disease: Angina Pectoris Ischemic Heart Disease: Angina Pectoris Robert J. Straka, Pharm.D. FCCP Associate Professor University of Minnesota College of Pharmacy Minneapolis, Minnesota, USA strak001@umn.edu Learning Objectives

More information

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia

More information

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Srinivasan Rajagopal M.D. Assistant Professor Division of Cardiothoracic Anesthesia Objectives Describe the pathophysiology

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Preoperative Pulmonary Evaluation: Truth and Fiction. What are this patientʼs risks? Goals for Today

Preoperative Pulmonary Evaluation: Truth and Fiction. What are this patientʼs risks? Goals for Today Preoperative Pulmonary Evaluation: Truth and Fiction Nichole G. Zehnder, MD Instructor in Internal Medicine Division of Hospital Medicine University of Colorado at Denver Hospital Medicine Group What are

More information

Geriatric Cardiology: Challenges and Strategies

Geriatric Cardiology: Challenges and Strategies Geriatric Cardiology: Challenges and Strategies No financial disclosures Geriatrics -- No Specific Age 'you know it when you see it' Functional Status Polypharmacy Impaired Renal Function Diagnostic Testing:

More information

Nursing Care and Considerations for Patients with Atrial Fibrillation. Kris Kinghorn RN, MSN, ANP-BC

Nursing Care and Considerations for Patients with Atrial Fibrillation. Kris Kinghorn RN, MSN, ANP-BC Nursing Care and Considerations for Patients with Atrial Fibrillation Kris Kinghorn RN, MSN, ANP-BC Case Study 66 y/o female (Mrs. Olus A. Blader) Admitted with c/o palpitations and lightheadedness PMH:

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012 Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced

More information

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF

More information

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant

More information

AANA Journal Course 4

AANA Journal Course 4 AANA Journal Course 4 Update for nurse anesthetists Preoperative cardiac evaluation *6 CE Credits Bob Halliburton, CRNA, DNSc Saint Louis, Missouri Donald Bell, CRNA, DNSc John Preston, CRNA, DNSc Knoxville,

More information

Electrocardiographic Issues in Williams Syndrome

Electrocardiographic Issues in Williams Syndrome Electrocardiographic Issues in Williams Syndrome R. Thomas Collins II, MD Assistant Professor, Pediatrics and Internal Medicine University of Arkansas for Medical Sciences Arkansas Children s Hospital

More information

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology

More information

Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Pocket Guideline Update

Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Pocket Guideline Update ACC/AHA Pocket Guideline Update Perioperative Cardiovascular Evaluation for Noncardiac Surgery A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

Section 8: Clinical Exercise Testing. a maximal GXT?

Section 8: Clinical Exercise Testing. a maximal GXT? Section 8: Clinical Exercise Testing Maximal GXT ACSM Guidelines: Chapter 5 ACSM Manual: Chapter 8 HPHE 4450 Dr. Cheatham Outline What is the purpose of a maximal GXT? Who should have a maximal GXT (and

More information

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf

More information

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Test Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Heart Failure - Definition European Heart Journal (2008) 29, 2388 2442 Akute Herzinsuffizienz Diagnostik und

More information

Anticoagulation Therapy Update

Anticoagulation Therapy Update Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2

More information

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015 Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015 Disclaimer I have no relationships to disclose Do we have a cure for Atrial Fibrillation? The short

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD. Stress Testing: Wael A. Jaber, MD,FACC 38 year old female with mild obesity She is planning an exercise program to loose weight. She has no other known risk factors for CAD. You recommend: A. Exercise

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

Perioperative Anticoagulation Management. Tony Ochoa, MD, FACC

Perioperative Anticoagulation Management. Tony Ochoa, MD, FACC Perioperative Anticoagulation Management Tony Ochoa, MD, FACC Interrupting Anticoagulation: To Bridge or Not? Peri-operative is most common reason Injury/Acute internal bleeding (not discussed) Atrial

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

Press conference: Rheumatic Heart Disease a forgotten but devastating disease

Press conference: Rheumatic Heart Disease a forgotten but devastating disease www.worldcardiocongress.org Chairpersons: Bongani M. Mayosi Jonathan Carapetis Press conference: Rheumatic Heart Disease a forgotten but devastating disease www.worldcardiocongress.org www.worldcardiocongress.org

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary

More information

Hypertension and Heart Failure Medications. Dr William Dooley

Hypertension and Heart Failure Medications. Dr William Dooley Hypertension and Heart Failure Medications Dr William Dooley Plan Heart Failure Acute vs. chronic Mx Hypertension Common drugs used Method of action Choice of medications Heart Failure Aims; Short term:

More information

Cardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology

Cardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology Cardiac Sources of Stroke Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology Stroke Pathophysiology Cardiologists Well Suited to Help 795K CVA per year, 87%

More information

Physician and other health professional services

Physician and other health professional services O n l i n e A p p e n d i x e s 4 Physician and other health professional services 4-A O n l i n e A p p e n d i x Access to physician and other health professional services 4 a1 Access to physician care

More information

Stroke Care First week

Stroke Care First week Stroke Care First week Florence Nightingale (1820 1910) Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 Facts 4 million or so people have atrial fibrillation 16 billion dollars spent yearly in USA 30% of strokes attributable to AF and AFL 3-5

More information

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy File name: Cardiac Rehabilitation (Outpatient Phase II) File code: UM.REHAB.04 Origination: 08/1994 Last Review: 08/2011 Next Review:

More information

Managing the Patient with Atrial Fibrillation

Managing the Patient with Atrial Fibrillation Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION

More information

http://find.galegroup.com.ezproxy.lib.usf.edu/itx/printdoc.do?contentset=iac-document...

http://find.galegroup.com.ezproxy.lib.usf.edu/itx/printdoc.do?contentset=iac-document... Page 1 of 27 An evidence-based approach to the preoperative evaluation.amir K. Jaffer and Bindu Sangani. Primary Care Reports 10.10 (Oct 2004): p111(16). (11071 words) Full Text:COPYRIGHT 2004 A Thomson

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

James F. Kravec, M.D., F.A.C.P

James F. Kravec, M.D., F.A.C.P James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice

More information

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012 The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received

More information

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT

More information